Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Acerta Pharma – A member of the AstraZeneca Group; Adaptive Biotechnologies; Celgene Corporation; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc.; NewLink Genetics; Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Seattle Genetics, Inc.; and Takeda Oncology.

Community Practice Connections™: 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma


Release Date: May 29, 2019
Expiration Date: May 29, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

CME Activity Table of Contents

  • Module 1. Non-Hodgkin Lymphoma
  • Module 2. Chronic Lymphocytic Leukemia
  • Module 3. Multiple Myeloma
  • Module 4. Acute Myeloid Leukemia/Myelodysplastic Syndromes

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Acerta Pharma – A member of the AstraZeneca Group; Adaptive Biotechnologies; Celgene Corporation; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc.; NewLink Genetics; Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Seattle Genetics, Inc.; and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals involved in the treatment and management of patients with hematologic malignancies may also participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Assess the application of biomarkers to determine risk and therapy for patients with hematologic malignancies
  • Integrate clinical trial evidence on current and emerging treatment approaches for the management of patients with hematologic malignancies
  • Evaluate approaches to mitigate and manage treatment-related adverse events in patients with hematologic malignancies
  • Discuss recent clinical trial results related to new therapeutic approaches and/or response assessment in patients with hematologic malignancies
  • Explain clinical implications of evolving therapeutic paradigms in hematologic malignancies

Faculty, Staff, and Planners’ Disclosures

Andre H. Goy
Andre H. Goy, MD, MS
Chairman and Executive Director
Lymphoma Division Chief – John Theurer Cancer Center
Chief Science Officer – RCCA
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Hackensack, NJ

Disclosures: Grant/Research Support: Johnson & Johnson, Celgene Corporation, Gilead/Kite clinical trial support through institution; Consultant: Celgene; Speakers Bureau: Takeda, Johnson & Johnson/Pharmacyclics, Gilead/Kite; Shareholder: Cota Healthcare; Other: Member on advisory board: Cota Healthcare, Celgene, Takeda, Pharmacyclics, Johnson & Johnson, Acerta Pharma – A member of the AstraZeneca Group, Gilead/Kite.

Sagar Lonial
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Consultant: Merck, Novartis, Onyx Pharmaceuticals, Millennium Pharmaceuticals, Bristol-Myers Squibb, Sanofi, Celgene, Janssen.

Richard M. Stone
Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Novartis (research), Agios Pharmaceuticals, Arog Pharmaceuticals; Consultant: Arog Pharmaceuticals, AstraZeneca, Astellas, AbbVie Inc., Amgen, Agios Pharmaceuticals, Fujifilm, Novartis, Pfizer, Sumitomo, Orsenix, Ono, Jazz Pharmaceuticals, Inc., Celgene Corporation, Janssen, Juno Therapeutics, Cornerstone Pharmaceuticals, MacroGenics, Otsuka/Astex; Other: Argenx, Takeda, Celgene (data and safety monitoring board), Actinium Pharmaceuticals (scientific advisory board).

William G. Wierda
William G. Wierda, MD, PhD
D.B. Lane Cancer Research Distinguished Professor, Department of Leukemia,
Division of Cancer Medicine
Head of CLL Section, Department of Leukemia
Leukemia Center Medical Director and Executive Medical Director for Hematologic Malignancies
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: GlaxoSmithKline /Novartis, AbbVie Inc., Genentech, Karyopharm, Pharmacyclics, Ascerta – A member of the AstraZeneca Group, Gilead Z Sciences, Inc., Juno Therapeutics, Kite Pharma, Sunesis Pharmaceuticals, miRagen Therapeutics; Consultant: Sanofi.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians’ Education Resource®, LLC (PER®), to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the companies that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
2930
Filter By